Analyst Ratings For Advanced Oncotherapy PLC (LON:AVO)
Today, Advanced Oncotherapy PLC (LON:AVO) stock was downgraded by Beaufort Securities from Hold to .
There are 1 hold rating on the stock.
The current consensus rating on Advanced Oncotherapy PLC (LON:AVO) is Hold (Score: 2.00) with a consensus target price of per share, a potential .
Some recent analyst ratings include
- 2/27/2017-Beaufort Securities was Downgraded by analysts at Beaufort Securities from a “Hold” rating to a “” rating.
- 6/3/2015-Westhouse Securities Reiterated Rating of Under Review.
About Advanced Oncotherapy PLC (LON:AVO)
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property. The Company’s segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system uses accelerators, which is a series of modular units. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company’s Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, the United States.
Recent Trading Activity for Advanced Oncotherapy PLC (LON:AVO)
Shares of Advanced Oncotherapy PLC closed the previous trading session at 51.00 down -6.50 -11.30% with 0 shares trading hands.